[1]杨可来尔,匡洪宇.糖尿病视网膜病变与NLRP3炎性小体[J].国际内分泌代谢杂志,2023,43(02):136-139.[doi:10.3760/cma.j.cn121383-20211214-12033]
　Yang Kelaier,Kuang Hongyu..NLRP3 inflammasome and diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2023,43(02):136-139.[doi:10.3760/cma.j.cn121383-20211214-12033]
点击复制

糖尿病视网膜病变与NLRP3炎性小体()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年02期
页码:
136-139
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
NLRP3 inflammasome and diabetic retinopathy
作者:
杨可来尔1; 匡洪宇2
1深圳大学总医院内分泌代谢病科,深圳 518000; 2哈尔滨医科大学附属第一医院内分泌科,哈尔滨 150000
Author(s):
Yang Kelaier1;  Kuang Hongyu2.
1Department of Endocrinology and Metabolism, Shenzhen University General Hospital, Shenzhen 518000, China; 2Department of Endocrinology, the First Affiliated Hospital of Harbin Medical University, Harbin 150000, China
关键词:
糖尿病视网膜病变;  NLRP3炎性小体;  炎症
Keywords:
Diabetic retinopathy;  NLRP3 inflammasome;  Inflammation
DOI:
10.3760/cma.j.cn121383-20211214-12033
摘要:
糖尿病视网膜病变(DR)是糖尿病常见的微血管并发症,是世界范围内致盲的主要原因。研究表明,NOD样受体蛋白3(NLRP3)炎性小体相关的炎性反应在DR的发病机制中起重要作用。NLRP3炎性小体是一种大型蛋白复合物,可被三磷酸腺苷(ATP)、活性氧(ROS)、前列腺素E2等上游分子调控并激活,并促进下游白细胞介素(IL)-1β和IL-18的分泌、释放并触发炎性反应。通过抑制NLRP3炎性小体的激活改善高血糖相关的视网膜损伤,可为DR的防治提供新思路。
Abstract:
Diabetic retinopathy(DR)is a common microvascular complications of diabetes mellitus, which is the main cause of blindness worldwide. Studies have shown that NLRP3 inflammasome-related inflammatory responses play an important role in the pathogenesis of DR. NLRP3 inflammasome is a large protein complex that is regulated and activated by upstream molecules such as ATP, ROS, and prostaglandin E2(PGE2)to promote the secretion and release of downstream interleukin(IL)-1β and IL-18 and trigger inflammatory responses. Inhibition the activation of NLRP3 inflammasome and improve the retinal injury associated with hyperglycemia, can provide new ideas for the prevention and treatment of DR.

参考文献/References:

[1] Roy S,Kim D.Retinal capillary basement membrane thickening:role in the pathogenesis of diabetic retinopathy[J].Prog Retin Eye Res,2021,82:100903.DOI:10.1016/j.preteyeres.2020.100903.
[2] Xu Z,Chen ZM,Wu X,et al.Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation[J].Front Immunol,2020,11:609441.DOI:10.3389/fimmu.2020.609441.
[3] Han X,Sun S,Sun Y,et al.Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy:implications for Parkinson disease[J].Autophagy,2019,15(11):1860-1881.DOI:10.1080/15548627.2019.1596481.
[4] Thounaojam MC,Montemari A,Powell FL,et al.Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy[J].Diabetes,2019,68(5):1014-1025.DOI:10.2337/db18-0912.
[5] Katsnelson MA,Lozada-Soto KM,Russo HM,et al.NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption:roles for K+ efflux and Ca2+ influx[J].Am J Physiol Cell Physiol,2016,311(1):C83-C100.DOI:10.1152/ajpcell.00298.2015.
[6] Zhong Z,Liang S,Sanchez-Lopez E,et al.New mitochondrial DNA synthesis enables NLRP3 inflammasome activation[J].Nature,2018,560(7717):198-203.DOI:10.1038/s41586-018-0372-z.
[7] Youm YH,Nguyen KY,Grant RW,et al.The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease[J].Nat Med,2015,21(3):263-269. DOI:10.1038/nm.3804.
[8] Chen J,Chen ZJ.PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation[J].Nature,2018,564(7734):71-76.DOI:10.1038/s41586-018-0761-3.
[9] Yang K,Liu J,Zhang X,et al.H3 relaxin alleviates migration,apoptosis and pyroptosis through P2X7R-mediated nucleotide binding oligomerization domain-like receptor protein 3 inflammasome activation in retinopathy induced by hyperglycemia[J].Front Pharmacol,2020,11:603689.DOI:10.3389/fphar.2020.603689.
[10] Liu Q,Zhang F,Zhang X,et al.Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation[J].Mol Cell Biochem,2018,445(1-2):105-115.DOI:10.1007/s11010-017-3256-x.
[11] Hu L,Yang H,Ai M,et al.Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose[J].Graefes Arch Clin Exp Ophthalmol,2017,255(11):2199-2210.DOI:10.1007/s00417-017-3772-0.
[12] Mugisho OO,Green CR,Kho DT,et al.The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release[J].Biochim Biophys Acta Gen Subj,2018,1862(3):385-393.DOI:10.1016/j.bbagen.2017.11.015.
[13] Raman KS,Matsubara JA.Dysregulation of the NLRP3 inflammasome in diabetic retinopathy and potential therapeutic targets[J].Ocul Immunol Inflamm,2022,30(2):470-478.DOI:10.1080/09273948.2020.1811350.
[14] Liu S,Tang G,Duan F,et al.MiR-17-5p inhibits TXNIP/NLRP3 inflammasome pathway and suppresses pancreatic β-cell pyroptosis in diabetic mice[J].Front Cardiovasc Med,2021,8:768029.DOI:10.3389/fcvm.2021.768029.
[15] Cao Y,Li X,Wang CJ,et al.Role of NF-E2-related factor 2 in neuroprotective effect of l-carnitine against high glucose-induced oxidative stress in the retinal ganglion cells[J].Biomed Pharmacother,2015,69:345-348.DOI:10.1016/j.biopha.2014.12.030.
[16] Zhang Y,Lv X,Hu Z,et al.Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction[J].Cell Death Dis,2017,8(7):e2941. DOI:10.1038/cddis.2017.308.
[17] Wang M,Wang Y,Xie T,et al.Prostaglandin E2/EP2 receptor signalling pathway promotes diabetic retinopathy in a rat model of diabetes[J].Diabetologia,2019,62(2):335-348. DOI:10.1007/s00125-018-4755-3.
[18] Mridha AR,Wree A,Robertson AAB,et al.NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J].J Hepatol,2017,66(5):1037-1046.DOI:10.1016/j.jhep.2017.01.022.
[19] Shen J,Choy DF,Yoshida T,et al.Interleukin-18 has antipermeablity and antiangiogenic activities in the eye:reciprocal suppression with VEGF[J].J Cell Physiol,2014,229(8):974-983.DOI:10.1002/jcp.24575.
[20] Hirano Y,Yasuma T,Mizutani T,et al.IL-18 is not therapeutic for neovascular age-related macular degeneration[J].Nat Med,2014,20(12):1372-1375.DOI:10.1038/nm.3671.

相似文献/References:

[1]刘琦,周赛君,孟振兴,等.P2X7受体与糖尿病视网膜病变[J].国际内分泌代谢杂志,2015,(02):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]
　Liu Qi,Zhou Saijun,Meng Zhenxing,et al.P2X7 receptor and diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2015,(02):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]

备注/Memo

备注/Memo:
通信作者:匡洪宇,Email:ydykuanghongyu@126.com
更新日期/Last Update: 2023-04-15